Quick Answer
enVVeno Medical Corp reported Research And Development Expense of $9.98 million for the year ending 2025.
- enVVeno Medical Corp showed a decrease of -18.5% in Research And Development Expense from 2024 to 2025.
- This data is from enVVeno Medical Corp's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $184.9 thousand | Q3 2017: $43.1 thousand | Q1 2018: $240.5 thousand | Q2 2018: $280.4 thousand | Q3 2018: $424.6 thousand | Q1 2019: $313.0 thousand | Q2 2019: $428.3 thousand | Q3 2019: $677.0 thousand | Q1 2020: $510.6 thousand | Q2 2020: $706.2 thousand | Q3 2020: $758.2 thousand | Q1 2021: $1.63 million | Q2 2021: $1.09 million | Q3 2021: $1.23 million | Q1 2022: $1.55 million | Q2 2022: $3.07 million | Q3 2022: $2.49 million | Q1 2023: $3.60 million | Q2 2023: $4.21 million | Q3 2023: $2.80 million | Q1 2024: $3.05 million | Q2 2024: $2.83 million | Q3 2024: $2.86 million | Q1 2025: $2.56 million | Q2 2025: $2.89 million | Q3 2025: $2.59 million.
- Over the full 9 years of available data (2017 to 2025), enVVeno Medical Corp's Research And Development Expense has grown by 1,436.2%.
- Historical annual values: Fiscal year 2025: $9.98 million | Fiscal year 2024: $12.25 million | Fiscal year 2023: $13.58 million | Fiscal year 2022: $9.91 million | Fiscal year 2021: $5.73 million | Fiscal year 2020: $4.25 million | Fiscal year 2019: $2.21 million | Fiscal year 2018: $1.24 million | Fiscal year 2017: $649.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: